Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Omidenepag. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 known ✓ | P43116 | 20/20 | 1.00 |
| ▸ | PTGER4 | P35408 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Omidenepag SCHEMBL30433956 | 1.00 | PTGER2 (1.00) | PTGER2PTGER4 | |
| Omidenepag SCHEMBL29565501 | 1.00 | PTGER2 (1.00) | PTGER2PTGER4 | |
| Omidenepag SCHEMBL533632 | 1.00 | PTGER2 (1.00) | PTGER2PTGER4 | |
| SCHEMBL22364205 | 0.89 | PTGER2 (0.81) | PTGER2PTGER4 | |
| SCHEMBL534263 | 0.89 | PTGER2 (1.00) | PTGER2PTGER4 | |
| Omidenepag Isopropyl SCHEMBL30434740 | 0.89 | PTGER2 (1.00) | PTGER2PTGER4 | |
| Omidenepag Isopropyl SCHEMBL15414827 | 0.89 | PTGER2 (1.00) | PTGER2PTGER4 | |
| Omidenepag Isopropyl SCHEMBL29375346 | 0.89 | PTGER2 (1.00) | PTGER2PTGER4 | |
| SCHEMBL22283788 | 0.88 | PTGER2 (0.79) | PTGER2PTGER4 | |
| SCHEMBL533704 | 0.88 | PTGER2 (0.79) | PTGER2PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11974994-B2 | Agent for treating or preventing glaucoma including a sulfonamide compound and another drug | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2024-05-07 | — | — | US | claimed |
| US-20240024484-A1 | PHARMACEUTICAL COMPOSITION CONTAINING PYRIDYLAMINOACETIC ACID COMPOUND | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2024-01-25 | — | — | US | claimed |
| US-20240000763-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A PYRIDYLAMINOACETIC ACID COMPOUND | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2024-01-04 | — | — | US | claimed |
| US-20230372316-A1 | PYRIDYLAMINOACETIC ACID COMPOUND AND POLYOXYETHYLENE CASTOR OIL-CONTAINING PHARMACEUTICAL COMPOSITION | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2023-11-23 | — | — | US | claimed |
| EP-3320904-B1 | PREVENTATIVE AND/OR THERAPEUTIC AGENT CONTAINING PYRIDYL AMINOACETIC ACID COMPOUND FOR TREATING A DISEASE INVOLVING A GREATLY ELEVATED INTRAOCULAR PRESSURE | SANTEN PHARMACEUTICAL CO LTD (JP) | 2023-07-05 | — | — | EP | claimed |
| EP-3888654-B1 | PYRIDYLAMINOACETIC ACID COMPOUND AND POLYOXYETHYLENE CASTOR OIL CONTAINING PHARMACEUTICAL COMPOSITION | SANTEN PHARMACEUTICAL CO LTD (JP) | 2023-06-14 | — | — | EP | claimed |
| US-11331311-B2 | Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2022-05-17 | — | — | US | claimed |
| US-20220054466-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A PYRIDYLAMINOACETIC ACID COMPOUND | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2022-02-24 | — | — | US | claimed |
| US-20210330654-A1 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2021-10-28 | — | — | US | claimed |
| EP-3888654-A1 | PYRIDYLAMINOACETIC ACID COMPOUND AND POLYOXYETHYLENE CASTOR OIL CONTAINING PHARMACEUTICAL COMPOSITION | Santen Pharmaceutical Co., Ltd. (JP) | 2021-10-06 | — | — | EP | claimed |
| US-20160317512-A1 | PYRIDYLAMINOACETIC ACID COMPOUND AND POLYOXYETHYLENE CASTOR OIL-CONTAINING PHARMACEUTICAL COMPOSITION | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2016-11-03 | — | — | US | claimed |
| US-20160228421-A1 | COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA COMPRISING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | claimed |
| US-9339496-B2 | Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2016-05-17 | — | — | US | claimed |
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | claimed |
| US-8648097-B2 | Pyridylaminoacetic acid compound | UBE INDUSTRIES, LTD. (JP) | 2014-02-11 | — | — | US | claimed |
| US-20140018396-A1 | COMBINATION OF SULFONAMIDE COMPOUND | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-01-16 | — | — | US | claimed |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | UBE INDUSTRIES, LTD. (JP) | 2012-07-26 | — | — | US | claimed |
| EP-2476678-A1 | SUBSTITUTED CARBONYL COMPOUNDS | Ube Industries, Ltd. (JP) | 2012-07-18 | — | — | EP | claimed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | claimed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160317512-A1 | PYRIDYLAMINOACETIC ACID COMPOUND AND POLYOXYETHYLENE CASTOR OIL-CONTAINING PHARMACEUTICAL COMPOSITION | PAOX, CYP4A11, PAH | PTGER2 296/4885PTGER4 237/4885 |
| US-20140018396-A1 | COMBINATION OF SULFONAMIDE COMPOUND | CHUK, PTGIS, PTGIR | PTGER2 58/4885PTGER4 78/4885 |
| US-20160228421-A1 | COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA COMPRISING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | PTGIS, PTGIR, PTGS1 | PTGER2 6/4885PTGER4 25/4885 |
| US-20240024484-A1 | PHARMACEUTICAL COMPOSITION CONTAINING PYRIDYLAMINOACETIC ACID COMPOUND | AADAT, DDC, PDE12 | PTGER2 505/4885PTGER4 567/4885 |
| US-11974994-B2 | Agent for treating or preventing glaucoma including a sulfonamide compound and another drug | PTGIS, PTGIR, PTGS1 | PTGER2 13/4885PTGER4 51/4885 |
| US-20240000763-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A PYRIDYLAMINOACETIC ACID COMPOUND | REN, AGTR2, PTGIS | PTGER2 314/4885PTGER4 515/4885 |
| US-20230372316-A1 | PYRIDYLAMINOACETIC ACID COMPOUND AND POLYOXYETHYLENE CASTOR OIL-CONTAINING PHARMACEUTICAL COMPOSITION | PAOX, CYP4A11, PAH | PTGER2 296/4885PTGER4 237/4885 |
| US-20220054466-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A PYRIDYLAMINOACETIC ACID COMPOUND | REN, AGTR2, PTGIS | PTGER2 314/4885PTGER4 515/4885 |
| US-11331311-B2 | Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound | AADAC, AADAT, PLPBP | PTGER2 1073/4885PTGER4 2062/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | PTGER2 1/4885PTGER4 17/4885 |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | F12, C1S, AKR1C3 | PTGER2 24/4885PTGER4 133/4885 |
| US-20210330654-A1 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | PTGIS, PTGIR, PTGS1 | PTGER2 13/4885PTGER4 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.